drug_type
RELEVANT_DRUG
intervention_type
Cellular therapy
drug_description
Autologous, lentivirally transduced CAR T-cell therapy for glioblastoma. The CAR (CARv3) targets EGFRvIII on tumor cells and the engineered T cells secrete TEAM-E, an EGFR×CD3 bispecific T-cell–engaging antibody that recruits and activates endogenous T cells against EGFR/EGFR-amplified tumor cells. Administered intraventricularly via an Ommaya reservoir.
nci_thesaurus_definition
NCI thesaurus definition not available.
drug_mesh_term
Chimeric Antigen Receptor T-Cell Therapy
drug_category
CAR T
drug_class
Cellular Therapy
drug_delivery_route
Intracerebroventricular
drug_mechanism_of_action
Autologous lentivirally transduced CAR T cells that recognize EGFRvIII on glioblastoma cells to mediate targeted T-cell cytotoxicity; the engineered cells also secrete TEAM-E, an EGFR×CD3 bispecific T-cell–engaging antibody that recruits and activates endogenous T cells against EGFR/EGFR-amplified tumor cells, broadening tumor targeting and reducing antigen escape.
drug_name
CARv3-TEAM-E T cells
nct_id_drug_ref
NCT05660369